Notizie AIOM – anno XVII
FDA approves new treatment for refractory multiple myeloma
July 3, 2019 - Today, the U.S. Food and Drug Administration granted accelerated approval to selinexor tablets in combination with the corticosteroid dexamethasone for the treatment of adult patients with relapsed refractory multiple myeloma (RRMM) who have received at least ...Leggi tutto
IMWG Consensus Recommendations on Imaging in Monoclonal Plasma Disorders
June 28, 2019 - Just as newer drugs have significantly improved outcomes for patients with multiple myeloma in the past decade, newer imaging techniques are upgrading detection of the disease, leading to earlier treatment, but standards to help guide clinicians on the optimal ...Leggi tutto
PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors
Treatment options are limited for patients with recurrent/metastatic low-grade ovarian cancers (LGOCs) and serous borderline ovarian tumors (SBOTs) as response rates to chemotherapy are low. A subset of patients appears to derive clinical benefit from antiestrogens, but ...Leggi tutto
A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component
We conducted a multicenter, phase 2 trial using gemcitabine plus axitinib (GX) in patients with recurrent or metastatic sarcomatoid renal cell carcinoma (SRCC) to evaluate its efficacy and safety. Methods Patients with advanced RCC and a sarcomatoid component of ≥25% ...Leggi tutto
Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
Pembrolizumab monotherapy has demonstrated durable antitumor activity in advanced programmed death ligand 1 (PD-L1) –expressing non‒small-cell lung cancer (NSCLC). We report 5-year outcomes from the phase Ib KEYNOTE-001 study. These data provide the longest efficacy ...Leggi tutto
FDA Approves Bevacizumab Biosimilar
June 28, 2019 - The FDA has approved PF-06439535 (bevacizumab-bvzr), a bevacizumab biosimilar for the treatment of patients with metastatic carcinoma of the colon or rectum; unresectable advanced, metastatic, or recurrent non–small cell lung cancer (NSCLC); advanced ...Leggi tutto
Atezolizumab Combo Approaches EU Approval for Frontline TNBC
June 28, 2019 - The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of the frontline combination of atezolizumab plus nab-paclitaxel for the treatment of adult patients with unresectable locally advanced or ...Leggi tutto
EU Panel Backs Expanded Indication of Ibrutinib Combos in CLL and Waldenstrom Macroglobulinemia
June 28, 2019 - The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the indications of ibrutinib to include use in combination with obinutuzumab for adult patients with previously untreated chronic lymphocytic ...Leggi tutto
ASCO Commends the National Academies of Sciences, Engineering, and Medicine for its Report on Guiding Cancer Control
June 28, 2019 - “We applaud the National Academies of Sciences, Engineering, and Medicine for its recommendations on cancer control in the United States. The report examines the oncology community’s efforts over the past 10 years and lays out a comprehensive ...Leggi tutto